Nutex Health
NUTX
213.02
-5.38
-2.46%
Nutex Health
US · NUTX
#2982 by market cap
Listed 1970
213.02
-5.38
-2.46%
Live - 5344 symbols - heartbeat 138s ago
· 2026-10-08 05:32
Pre-market
213.00
-0.01%
After-hours
213.02
0.00%
- Market cap
- 1.46B
- P/E (TTM)i
- 8.26
- P/Bi
- 3.70
- EPSi
- 10.48
- Div yieldi
- 0.00%
- 52W posi
- 91%
Reader sentiment
Are you bullish or bearish on NUTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.77, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year +82.36% YoY
Margins
- Gross margin
- 50.76%
- Operating margin
- 31.49%
- Net margin
- 8.09%
Key ratios & quality
- Enterprise valuei
- 1.33B
- Altman Z-Scorei
- 3.77
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 97.06M | 274.03M | 331.53M | 219.29M | 247.65M | 479.95M | 875.26M |
| Gross profit | -- | 157.61M | 179.28M | 15.42M | 34.77M | 196.26M | 444.28M |
| Selling & admin expenses | 59.87M | 4.43M | 5.46M | 20.00M | 36.07M | 58.48M | 168.66M |
| Research & development | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 34.71M | 153.17M | 173.82M | -4.58M | -1.51M | 137.78M | 275.63M |
| Pretax profit | 32.09M | 145.74M | 169.49M | -419.65M | -48.49M | 109.83M | 244.78M |
| Tax | -- | 181.34K | 965.73K | 13.09M | -5.07M | 15.02M | 64.42M |
| Net profit | 32.09M | 145.56M | 168.53M | -432.74M | -43.42M | 94.81M | 180.36M |
| Basic EPS | 5 | 25 | 31 | -100 | -10 | 10 | 11 |
| Diluted EPS | 4.88 | 24.69 | 30.90 | -100.36 | -10.39 | 9.69 | 10.48 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 211.79M | 243.99M | 267.80M | 151.68M | 216.49M | 210.75M |
| Gross profit | 118.34M | 124.92M | 154.88M | 46.14M | 91.73M | 141.28M |
| Selling & admin expenses | 37.68M | 91.25M | 24.51M | 15.22M | 10.47M | 19.56M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 80.66M | 33.68M | 130.37M | 30.92M | 81.27M | 121.72M |
| Pretax profit | 71.22M | 23.73M | 123.94M | 25.89M | 76.56M | 117.09M |
| Tax | 20.41M | 7.59M | 27.14M | 9.29M | 13.80M | 20.77M |
| Net profit | 50.81M | 16.14M | 96.80M | 16.61M | 62.76M | 96.32M |
| Basic EPS | 4 | -3 | 8 | 2 | 7 | 10 |
| Diluted EPS | 3.33 | -2.95 | 7.76 | 1.50 | 6.52 | 9.38 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 45.74M | 135.51M | 154.02M | 97.97M | 90.85M | 292.48M | 538.81M |
| Cash & ST investments | 8.00M | 25.51M | 36.12M | 34.26M | 22.00M | 40.64M | 185.57M |
| Inventory | 899.92K | 1.73M | 2.81M | 3.53M | 3.39M | 2.85M | 2.87M |
| Total assets | 179.22M | 308.55M | 394.65M | 431.75M | 398.25M | 655.32M | 918.53M |
| Total current liabilities | 72.13M | 31.45M | 37.69M | 54.86M | 58.31M | 154.23M | 157.91M |
| Short-term debt | 63.68M | 20.39M | 13.17M | 21.09M | 20.08M | 27.73M | 23.31M |
| Long-term debt | 40.88M | 81.90M | 78.82M | 23.05M | 26.31M | 22.47M | 29.17M |
| Total liabilities | 128,388,954.00 | 161,185,980.00 | 203,069,033.00 | 311,424,585.00 | 319,139,391.00 | 466,787,000.00 | 495,088,000.00 |
| Total equity | 50.84M | 147.37M | 191.58M | 120.33M | 79.11M | 188.53M | 423.44M |
| Retained earnings | -- | -- | 102.32M | -363.29M | -409.07M | -356.98M | -286.19M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 401.52M | 473.03M | 592.65M | 538.81M | 579.65M | 585.65M |
| Cash & ST investments | 84.73M | 96.73M | 166.05M | 185.57M | 207.35M | 205.21M |
| Inventory | 3.12M | 2.28M | 3.16M | 2.87M | 4.68M | 4.21M |
| Total assets | 761.92M | 841.03M | 964.52M | 918.53M | 957.32M | 964.63M |
| Total current liabilities | 176.57M | 194.87M | 185.46M | 157.91M | 184.44M | 117.22M |
| Short-term debt | 30.89M | 35.97M | 32.53M | 23.31M | 26.41M | 18.10M |
| Long-term debt | 21.73M | 20.46M | 25.57M | 29.17M | 24.26M | 31.11M |
| Total liabilities | 487,036,000.00 | 504,151,000.00 | 526,485,000.00 | 495,088,000.00 | 515,265,000.00 | 457,317,000.00 |
| Total equity | 274.88M | 336.88M | 438.03M | 423.44M | 442.05M | 507.31M |
| Retained earnings | -342.26M | -353.46M | -298.02M | -286.19M | -239.38M | -173.54M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 12.12M | 86.67M | 173.43M | 50.61M | 1.26M | 23.15M | 248.13M |
| Depreciation & amortization | 2.48M | 5.90M | 7.66M | 13.13M | 17.59M | 18.97M | 20.53M |
| Free cash flow | -20.15M | 25.48M | 136.51M | 35.97M | -8.24M | 20.85M | 245.60M |
| Dividends paid | -18.90M | -59.05M | -144.34M | -51.23M | -5.22M | -6.44M | -74.28M |
| Stock buybacks / issuance | -- | -- | -- | 0 | 0 | 9.20M | -5.00M |
| Ending cash balance | 8.00M | 25.51M | 36.12M | 34.26M | 22.00M | 40.64M | 185.87M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 50.97M | 27.26M | 99.51M | 70.39M | 75.52M | 34.20M |
| Depreciation & amortization | 5.09M | 5.25M | 5.00M | 5.19M | 5.49M | 5.32M |
| Free cash flow | 50.90M | 26.51M | 99.21M | 68.98M | 74.32M | 31.66M |
| Dividends paid | -7.36M | -11.41M | -23.40M | -32.10M | -15.36M | -13.26M |
| Stock buybacks / issuance | 0 | -- | -- | -5.00M | -31.73M | -- |
| Ending cash balance | 84.73M | 96.73M | 166.05M | 185.87M | 207.35M | 207.11M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | 73.91 | 176.69 | 132.29 | -403.57 | -58.21 | 50.22 | 29.76 |
| ROA %i | 11.67 | 41.34 | 37.71 | -102.80 | -11.03 | 9.91 | 9.00 |
| ROIC %i | 15.85 | 54.93 | 52.45 | -126.45 | -8.90 | 16.87 | 14.93 |
| 5-year avg ROE %i | -- | -- | -- | -- | -13.97 | -18.01 | -49.02 |
| EBIT margin %i | 36.70 | 55.59 | 52.99 | -185.67 | -12.99 | 27.02 | 30.51 |
| FCF / sales %i | -- | 7.34 | 41.17 | 16.40 | -- | 4.34 | 28.06 |
| Current ratioi | 0.63 | 4.31 | 4.09 | 1.79 | 1.56 | 1.90 | 3.41 |
| Quick ratioi | 0.61 | 4.25 | 4.00 | 1.69 | 1.45 | 1.79 | 3.24 |
| Debt / assetsi | 66.92 | 48.65 | 45.24 | 61.89 | 69.24 | 51.93 | 38.26 |
| LT debt / equityi | 198.72 | 151.19 | 144.24 | 256.73 | 416.06 | 236.00 | 99.59 |
| Interest coveragei | 10.09 | 23.63 | 28.35 | -32.60 | -1.97 | 6.51 | 12.01 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 31.22 | -3.32 | 13.12 | 58.62 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -26.76 | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -46.55 | 89.70 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 51.65 | 37.87 | 63.90 | 29.76 | 35.47 | 57.16 |
| ROA %i | 11.52 | 8.93 | 17.20 | 9.00 | 11.21 | 19.93 |
| ROIC %i | 19.39 | 15.90 | 26.67 | 14.93 | 18.21 | 29.59 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 31.12 | 28.17 | 35.65 | 30.51 | 30.79 | 42.90 |
| FCF / sales %i | 11.12 | 10.51 | 17.97 | 28.06 | 30.57 | 32.38 |
| Current ratioi | 2.27 | 2.43 | 3.20 | 3.41 | 3.14 | 5.00 |
| Quick ratioi | 2.18 | 2.32 | 3.09 | 3.24 | 3.00 | 4.79 |
| Debt / assetsi | 44.80 | 41.05 | 37.18 | 38.26 | 36.47 | 36.01 |
| LT debt / equityi | 157.51 | 131.47 | 102.81 | 99.59 | 93.18 | 83.49 |
| Interest coveragei | 8.99 | 10.04 | 15.68 | 12.01 | 13.03 | 18.36 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Hospital division is the largest reported line at 95.78% of revenue, across 4 reported segments.
- The next-largest line, Population health management division, is a distant second at 4.22% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Hospital division95.78%
Population health management division4.22%
Real Estate Division0.56%
Quote time 2026-10-08 05:32:22 · For reference only, not investment advice and not tailored to your situation.